Kalaris Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kalaris Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.5 times its market value (net cash). Higher than 97% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-121.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 86% of Healthcare companies in United States.
Cash Cushion Ratio
2.5× cashCash, after subtracting all debt, is 2.5 times its market value (net cash).
Higher than 97% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Kalaris Therapeutics, Inc. made a loss over the last year. Kalaris Therapeutics, Inc. owes $0.42 for every $1 it owns. Kalaris Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKalaris Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.82The share price is 0.82 times Kalaris Therapeutics, Inc.'s book value per share, lower than 83% of Healthcare companies in United States.
Market cap
$47 MThe total market value of all of Kalaris Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$58 MWhat Kalaris Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.42Net worth divided by the number of shares. The share price of $1.99 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-79.9%Kalaris Therapeutics, Inc. lost 79.9% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
Owes vs Owns
0.42×Kalaris Therapeutics, Inc. owes $0.42 for every $1 it owns (low), higher than 50% of Healthcare companies in United States.
Dividend yield
NoneKalaris Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossKalaris Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredKalaris Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashKalaris Therapeutics, Inc. held $117 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kalaris Therapeutics, Inc.: $47 M ÷ $58 M (30 Jun 2026) = 0.8.
What is Kalaris Therapeutics, Inc.'s return on equity?
Kalaris Therapeutics, Inc. lost 79.9% of its shareholders' money over the last year, lower than 65% of Healthcare companies in United States.
How much does Kalaris Therapeutics, Inc. owe compared with what it owns?
Kalaris Therapeutics, Inc. owes $0.42 for every $1 it owns (low), higher than 50% of Healthcare companies in United States.
Does Kalaris Therapeutics, Inc. pay a dividend?
No. Kalaris Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.